Free Trial
NASDAQ:NLNK

NewLink Genetics (NLNK) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$2.28
$2.52
50-Day Range
$0.89
$14.10
52-Week Range
$0.82
$3.60
Volume
65,546 shs
Average Volume
547,540 shs
Market Capitalization
$91.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NLNK stock logo

About NewLink Genetics Stock (NASDAQ:NLNK)

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

NLNK Stock News Headlines

See More Headlines
Receive NLNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2019
Today
5/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NLNK
CUSIP
65151110
Fax
N/A
Employees
55
Year Founded
N/A

Profitability

Net Income
$-42,990,000.00
Net Margins
-4,592.84%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$940,000.00
Book Value
$2.11 per share

Miscellaneous

Free Float
N/A
Market Cap
$91.49 million
Optionable
Not Optionable
Beta
1.17
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Charles J. Link Jr. (Age 60)
    Co-Founder, Chairman, CEO & Chief Scientific Officer
  • Mr. Nicholas N. Vahanian (Age 52)
    Co-Founder, Pres, Chief Medical Officer & Director
  • Dr. Eugene P. Kennedy M.D. (Age 50)
    FACS, Chief Medical Officer
  • Mr. Brian Wiley (Age 51)
    Chief Commercial Officer
  • Mr. Carl W. Langren (Age 64)
    CFO & Principal Accounting Officer

NLNK Stock Analysis - Frequently Asked Questions

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) posted its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%.

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD).

This page (NASDAQ:NLNK) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners